Fujian Cancer Hospital (Fujian Cancer Institute, Fujian Cancer Prevention and Treatment Center)

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Phase 2

Recruiting

Conditions: Esophageal Neoplasms
Digestive System Neoplasms
Esophageal Diseases

Interventions: Drug: camrelizumab
Drug: Paclitaxel drugs
Drug: Platinum drug
Radiation: Radiation

First Posted Date: 2022-11-21

Last Posted Date: 2023-10-19

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 75

Registration Number: NCT05624099

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, China

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

Phase 2

Not yet recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Fluzopari and apatinib

First Posted Date: 2022-10-28

Last Posted Date: 2022-10-28

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 35

Registration Number: NCT05597527

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Phase 2

Not yet recruiting

Conditions: Angiogenesis
Chemotherapy Effect
Small Cell Lung Cancer

Interventions: Drug: Surufatinib
Drug: Irinotecan

First Posted Date: 2022-10-27

Last Posted Date: 2022-11-29

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT05595889

Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain

Phase 1

Not yet recruiting

Conditions: Hawthorn Red Combined Refractory Cancer Pain

Interventions: Drug: Hawthorn red pigment

First Posted Date: 2022-09-30

Last Posted Date: 2022-09-30

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 14

Registration Number: NCT05561023

Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines

Phase 3

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: level Ib-covering IMRT
Radiation: level Ib-sparing IMRT

First Posted Date: 2022-08-29

Last Posted Date: 2022-09-19

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 398

Registration Number: NCT05519956

the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Conditions: With EGFR Mutations
The Age of 18 Years Old or More
Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment
ECOG PS 0 to 2 Points
The TNM (8th) Phase is IV
Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology
Male or Female

First Posted Date: 2022-08-11

Last Posted Date: 2022-08-11

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 9

Registration Number: NCT05497076

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Immunotherapy

Interventions: Drug: Capecitabine
Drug: Tislelizumab
Radiation: short-range radiotherapy
Drug: oxaliplatin

First Posted Date: 2022-07-29

Last Posted Date: 2023-06-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 94

Registration Number: NCT05479240

To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer

Phase 2

Conditions: Colon Cancer

Interventions: Drug: Envafolimab

First Posted Date: 2022-04-19

Last Posted Date: 2022-04-19

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 36

Registration Number: NCT05335460

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Phase 1

Recruiting

Conditions: Gastric Cancer Stage IV

Interventions: Drug: Oxaliplatin
Drug: Levo-Leucovorin
Drug: 5-fluorouracil
Drug: Paclitaxel
Drug: Irinotecan
Drug: Tislelizumab

First Posted Date: 2022-04-08

Last Posted Date: 2023-09-18

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT05319639

Locations: 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer
Immunotherapy

Interventions: Drug: Tislelizumab
Drug: bevacizumab
Drug: TAS-102

First Posted Date: 2022-04-06

Last Posted Date: 2022-08-23

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 25

Registration Number: NCT05314101

Locations: 🇨🇳
FujianCH, Fuzhou, Fujian, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy